Showing 5091-5100 of 8783 results for "".
- Acne Pipeline Watch: Dermata Therapeutics Completes Enrollment in Phase 2b Trial of Once-Weekly Topical DMT310 for Acnehttps://practicaldermatology.com/news/acne-pipeline-watch-dermata-therapeutics-completes-enrollment-in-phase-2b-trial-of-once-weekly-topical-dmt310-for-acne/2460282/Dermata Therapeutics, LLC completed enrollment of patients in its Phase 2b clinical trial evaluating the safety, tolerability and efficacy of DMT310 in moderate to severe acne patients. The Phase 2b trial enrolled 182 patients randomly in two group
- Sun Pharma's New Ad Campaign Raises Awareness of Acne and its Impacthttps://practicaldermatology.com/news/sun-pharmas-new-ad-campaign-raises-awareness-of-acne-and-its-impact-1/2460280/Sun Dermatology, a division of Sun Pharmaceutical Industries, Inc., USA, launched Take on Acne – a new advertising campaign designed to raise awareness of the profound impact of acne on everyday life, particularly among teenagers and young adults (roughly 12-25 years of age). Acne af
- Revance: FDA Accepts BLA for DaxibotulinumtoxinA, Sets November PDUFA Datehttps://practicaldermatology.com/news/revance-fda-accepts-bla-for-daxibotulinumtoxina-sets-november-pdufa-date/2460278/FDA has accepted the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines, Revance reports. The FDA set an action date of November 25, 2020 under the Prescription Drug User Fee Act (PDUFA) VI program.
- Aerolase and Eucerin Join Forces to Optimize Patient Outcomes in Laser Treatmentshttps://practicaldermatology.com/news/aerolase-and-eucerin-join-forces-to-optimize-patient-outcomes-in-laser-treatments-1/2460277/Aerolase and Eucerin are working together to optimize laser treatment protocols in the D-A-CH-region (Germany-Austria-Switzerland). Furthermore, both companies will develop therapies for adjunctive care post-laser treatments. Both companies will also conduct a joint symposium
- Cold Plasma Patch May Make Immunotherapy More Effective for Treating Melanomahttps://practicaldermatology.com/news/cold-plasma-patch-may-make-immunotherapy-more-effective-for-treating-melanoma/2460275/A new medicated patch that can deliver immune checkpoint inhibitors and cold plasma directly to tumors may help boost the immune response and kill cancer cells, according to an interdisciplinary team of researchers at the UCLA Jonsson Comprehensive Cancer Center. The thumb-sized patch h
- Allergan Launches New Philanthropic Program Benefitting Kids with Upper Limb Spasticityhttps://practicaldermatology.com/news/allergan-launches-new-philanthropic-program-benefitting-kids-with-upper-limb-spasticity/2460274/Allergan is launching the Be The Difference philanthropic program to support children and their families who may benefit from treatment with Botox (onabotulinumtoxinA) for pediatric upper limb spasticity. Botox is approved to treat increased muscle stiffness in children 2 to 17 years of
- Ortho Dermatologics Opens 2020 Aspire Higher Scholarship Programhttps://practicaldermatology.com/news/ortho-dermatologics-opens-2020-aspire-higher-scholarship-program/2460273/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics opened of the application process for its 2020 Aspire Higher scholarship program. The program, which began in 2012, will award nine students who have been treated for a dermatologic condition with a
- Neuromodulators and Fillers Top RealSelf's List of Most Worth It Procedures of 2020https://practicaldermatology.com/news/neuromodulators-and-fillers-top-realselfs-list-of-most-worth-it-procedures-of-2020-1/2460272/A total of 15 nonsurgical and 37 surgical procedures earned Real Self’s Most Worth It designation for 2020. The RealSelf Worth It Rating is a proprietary consumer satisfaction score based on reviews from consumers on RealSelf who, after undergoing a treatment, rated it as "Wo
- Derms Still Need Disaster Preparedness Traininghttps://practicaldermatology.com/news/derms-still-need-disaster-preparedness-training/2460271/The dermatology community is inadequately prepared for a biological disaster and would benefit from a formal preparedness training program, according to a study from the George Washington University (GW) that appears in the Jour
- BioPharmX Corporation and Timber Pharmaceuticals LLC Announce Mergerhttps://practicaldermatology.com/news/biopharmx-corporation-and-timber-pharmaceuticals-llc-announce-merger/2460267/BioPharmX Corporation and Timber Pharmaceuticals LLC have entered into a definitive merger agreement. Under the terms of the merger agreement, subject to the approval of BioPharmX's stockholders and Timber's members, a wholly-owned subsidiary of BioPharmX will be merged wit